TVAX Biomedical Announces Receipt of $2 Million FDA Orphan Products Grant for Glioblastoma Study
18 oct. 2022 10h07 HE
|
TVAX Biomedical
OLATHE, Kan., Oct. 18, 2022 (GLOBE NEWSWIRE) -- TVAX Biomedical (TVAX) is a cancer immunotherapy company that is moving into its pivotal glioblastoma study for FDA regulatory approval. In September...
CNS Pharmaceuticals Inc. Featured in Syndicated Broadcast Covering Activation of First Clinical Trial Sites in Europe Evaluating Berubicin for the Treatment of GBM
07 oct. 2022 08h00 HE
|
CNS Pharmaceuticals, Inc.
LOS ANGELES, Oct. 07, 2022 (GLOBE NEWSWIRE) -- InvestorWire -- CNS Pharmaceuticals Inc. (NASDAQ: CNSP), a clinical stage biotechnology company specializing in the development of novel treatments for...
Ivy Brain Tumor Center Implements New Liquid Biopsy Program to Provide Glioblastoma Patients More Personalized Care
07 sept. 2022 09h00 HE
|
Ivy Brain Tumor Center
PHOENIX, Ariz., Sept. 07, 2022 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at Barrow Neurological Institute, the largest early-phase drug development program for brain cancer, announced its...
Brain Cancer Diagnostics Market Revenue to Cross $7.37 Bn Globally, by 2028 at 28.5.% CAGR - Exclusive Report by The Insight Partners
15 juil. 2022 08h30 HE
|
The Insight Partners
New York, July 15, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Brain Cancer Diagnostic Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by...
Cure Brain Cancer Foundation Invests in Innovative Clinical Trial Program to Treat Glioblastoma
16 mai 2022 06h00 HE
|
Cure Brain Cancer Foundation
LOS ANGELES, May 16, 2022 (GLOBE NEWSWIRE) -- This Brain Cancer Awareness Month (May), a handful of the brightest and best minds in brain cancer research will meet all around the US to discuss...
Telix Collaborates with Olivia Newton-John Cancer Research Institute on Brain Cancer Imaging Study
21 déc. 2021 19h49 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into a clinical data access agreement with...
Ivy Brain Tumor Center’s Core Laboratories Awarded Accreditation by the College of American Pathologists
21 déc. 2021 12h27 HE
|
Ivy Brain Tumor Center
Phoenix, Dec. 21, 2021 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center, the largest early-phase drug development program for brain cancer in the world, announced that its Pharmacodynamics (PD) Core...
Ivy Brain Tumor Center Collaborates with GSK on New Phase 0 Clinical Trial to Evaluate Niraparib in Patients with Brain Cancer
02 nov. 2021 07h00 HE
|
Ivy Brain Tumor Center
PHOENIX, Ariz., Nov. 02, 2021 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at Barrow Neurological Institute and UC San Francisco announced the opening of a Phase 0 clinical trial to evaluate...
Blood Brain Barrier Technologies Market Size ($5,101.94Mn by 2028) Lead by Neurological Disorders (25.5% CAGR) Impact of Coronavirus Outbreak and Global Analysis & Forecast by TheInsightPartners.com
21 oct. 2021 11h42 HE
|
The Insight Partners
New York, Oct. 21, 2021 (GLOBE NEWSWIRE) -- The new research study on the Blood Brain Barrier Technologies Market Size and Forecast to 2028 By Technology (Bispecific Antibody RMT Approach, Trojan...
Ivy Brain Tumor Center and SonALAsense Announce Positive Initial Results of the First-in-Human Phase 0/1 Clinical Trial of Non-Invasive Sonodynamic Therapy for Recurrent Glioblastoma
20 sept. 2021 12h00 HE
|
Ivy Brain Tumor Center
PHOENIX, Ariz., Sept. 20, 2021 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at Barrow Neurological Institute, the largest early-phase drug development program for brain cancer in the world, and...